Related Experiment Video
Updated: Sep 18, 2025
08:48
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
3.4K
TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease
Ana Luísa Rodriguez Gini1, Pamela Souza Tada da Cunha1, Emílio Emílio João1
1Department of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
Summary
Targeted protein degradation offers a novel approach to combat Chagas disease by degrading essential Trypanosoma cruzi proteins. This theoretical framework, "TrypPROTACs," outlines potential targets and methods for developing new treatments.
Area of Science:
- Parasitology and Tropical Diseases
- Molecular Biology and Drug Discovery
- Biochemistry and Chemical Biology
Background:
- Chagas disease, caused by Trypanosoma cruzi, presents significant therapeutic challenges due to current treatment limitations.
- Existing drugs exhibit toxicity, poor tolerability, and insufficient efficacy against T. cruzi.
- Novel strategies are urgently needed to address the unmet medical needs in Chagas disease treatment.
Purpose of the Study:
- To introduce the conceptual framework of "TrypPROTACs" for targeting essential Trypanosoma cruzi proteins.
- To identify and analyze druggable targets across critical parasite biological pathways.
- To explore the feasibility of applying targeted protein degradation (TPD) to combat neglected tropical diseases.
Main Methods:
- Comprehensive analysis of druggable targets in T. cruzi, including ergosterol biosynthesis, redox metabolism, and protein kinases.
- Review of existing inhibitors for identified target classes, focusing on potency, selectivity, and structural features.
- Examination of the parasite's ubiquitination machinery and comparison with human E3 ubiquitin ligases for PROTAC development.
Main Results:
- Identification of multiple critical biological pathways and specific targets within T. cruzi amenable to TPD.
- Compilation of representative inhibitors and discussion of their relevance for designing proteolysis-targeting chimeras (PROTACs).
- Exploration of linker engineering, ternary complex stabilization, and validation techniques (CETSA, NanoBRET) for TrypPROTAC development.
Conclusions:
- The theoretical framework of TrypPROTACs presents a promising, albeit currently unvalidated, strategy for Chagas disease treatment.
- Rational design of TrypPROTACs requires a deep understanding of parasite biology, target druggability, and TPD mechanisms.
- This approach holds potential for expanding TPD strategies to other neglected tropical diseases, offering new therapeutic avenues.
